Hamamatsu introduces a new imaging based plate reader, the FDSS/µCELL; an easy to use, fast and cost-effective solution for compound screening and assay development in the Pharmaceutical and Biotech Industries.
Hamamatsu introduces a new imaging based plate reader, the FDSS/μCELL; an easy to use, fast and cost-effective solution for compound screening and assay development in the Pharmaceutical and Biotech Industries.
The FDSS/μCELL is optimised for fluorescent kinetic assays using calcium and membrane potential dyes such as FLUO4 and FMP.
Dispensing is available in either 96 or 384 well format with exchangeable heads. Agonist / antagonist assays can be performed in the same run and the optional washing system reduces carry over and allows tips to be reused several times.
Based on the renowned FDSS series, the μCELL uses proven and reliable technology. It is equipped with a high-sensitivity Hamamatsu camera that images the entire plate simultaneously to provide fast readout times of a few minutes, compared to the longer readout times offered by conventional scanning based systems.
Designed for fast and simple operation; assay and compound plates can be easily loaded and the assay is ready to start. The software helps you to quickly set assay parameters in a single protocol which can then be easily transferred to the FDSS7000 for further screening.
The FDSS/μCELL is the reader of choice, offering easy set-up and high speed readout for your kinetic assays in fluorescence.
Click here for more information
Contact Details
Freephone Europe: 00 800 800 800 88
Email: europe@hamamatsu.comwww.sales.hamamatsu.com
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.